# A Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediatric Patients With Sickle Cell Disease Who Are at Increased Risk for Primary Stroke

> **NCT05953584** · PHASE2 · RECRUITING · sponsor: **Forma Therapeutics, Inc.** · enrollment: 27 (estimated)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **DRUG:** Etavopivat
- **DRUG:** Hydroxyurea

## Key facts

- **NCT ID:** NCT05953584
- **Lead sponsor:** Forma Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-20
- **Primary completion:** 2027-09-20
- **Final completion:** 2027-09-20
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2025-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05953584

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05953584, "A Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediatric Patients With Sickle Cell Disease Who Are at Increased Risk for Primary Stroke". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05953584. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*